COVID-19 DISEASE Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, severe acute respiratory syndrome from COVID-19, that was first recognized in Wuhan, China, in December 2019. While most people with COVID-19 develop mild or uncomplicated illness, approximately 14% develop severe disease requiring hospitalization and oxygen support and 5% require admission to an intensive care unit. In severe cases, COVID-19 can be complicated by acute respiratory disease syndrome (ARDS) requiring prolonged mechanical ventilation, sepsis and septic shock, multiorgan failure, including acute kidney, liver and cardiac injury. ARDS REHABILITATION Critically ill people who undergo prolonged mechanical ventilation often develop weakness, with severe symmetrical weakness of and deconditioning of the proximal musculature and of the respiratory muscles (critical illness neuropathy/myopathy).These individuals also develop significant functional impairment and reduced health-related quality of life (HRQL) up to 2 and 5 years after discharge. ARDS survivors may complain of depression, anxiety, memory disturbances, and difficulty with concentration often unchanged at 2 and 5 years. Less than half of all ARDS survivors return to work within the first year following discharge, two-thirds at two years, and more than 70% at five years. Early physiotherapy (PT) of people with ARDS has recently been suggested as a complementary therapeutic tool to improve early and late outcomes. The aims of PT programs should be to reduce complications of immobilization and ventilator-dependency, to improve residual function, to prevent new hospitalisations, and to improve health status and HRQL. Physiotherapy in critical patients is claimed also to prevent and contribute to treat respiratory complications such as secretion retention, atelectasis, and pneumonia. Early mobilization and maintenance of muscle strength may reduce the risk of difficult weaning, limited mobility, and ventilator dependency. Lastly, pulmonary rehabilitation in ICU in mechanically ventilated subjects may reduce length of stay in ICU up to 4.5 day, shorten mechanical ventilation of 2.3 days and weaning by 1.7 days. The aim of this study is to investigate how early pulmonary and motor rehabilitation impacts on length of hospital admission (ICU and acute ward) and early and late outcomes inpatients that develop ARDS due to COVID-19.
People that develop ARDS due to COVID-19 and requiring admission to ICU (both invasive and
non-invasive mechanical ventilation) will be enrolled. Two tertiary referral centers, part of
the same region (Veneto) but located in different cities, will recruit participants. ICU
standard of care is the same as defined by regional and national guidelines; rehabilitation
in ICU COVID-19 subjects is provided only in one center due to local technical and
organizational limitations. Non contamination between centers is possible due to restrictions
of mobility and strict admission criteria based on catchment area.
Early physiotherapy treatment will start from the day of admission. Baseline measurement of
physical function will performed using the Physical Function in ICU Test (PFIT). The PFIT is
a submaximal exercise test that was developed for patients in the ICU who may not be able to
mobilize away from the bedside.
Participants will start rehabilitation if they will not experiment one of the following
conditions or should cease exercise because of the following (see exclusion criteria).
Rehabilitation Intervention
Rehabilitation program will start at admission in ICU. The program is based on the clinical
characteristics of the individual to be treated. Participants will commence a hierarchical,
standardized protocol that includes functional, respiratory and strength training. If
participants will be unable to sit out of bed, assisted active exercises will be performed in
bed. Exercise training will be provided for 15 minutes 3 times/day, 6 days per week.
Intensity of strength training: Until fatigue (Borg Scale) Type of strength training: >Grade
3 Medical Research Council (MRC) strength, active to resisted;
to 3 sets of 10 repetitions as able Functional retraining: Sit-to-stand (using tilt table or
standing walker if unable), rolling, supine to sitting, trunk control/balance
Motor program
- Intubated patient Glasgow Coma Scale (GCS) >8: passive mobilisation; postural
positioning Glasgow Coma Scale < 8 (weaning): passive and active-assist mobilisation;
postural positioning
- Weaned off patient Non-invasively ventilated/O2 high fluxes
- If strength < 3 MRC: passive and/or active-assist; tentative functional retraining
- If strength ≥3 MRC: active-assist and active; strength training; functional
retraining Pulmonary Rehabilitation
- Intubated patient Glasgow Coma Scale >8: postural positioning Glasgow Coma Scale < 8
(weaning): postural positioning, cautious inspiratory muscle training
- Weaned off patient Non-invasively ventilated/O2 high fluxes
- If strength < 3 MRC: postural positioning, positive pressure expiration exercise,
cautious inspiratory muscle training
- If strength ≥3 MRC: postural positioning, positive pressure expiration exercise,
inspiratory muscle training
The intensity of exercise will prescribed based on the results of the PFIT. Rehabilitation
programs will individualized for each patient. Programs will progressed using rates of
perceived exertion (RPE) of the modified Borg Scale.
Total session time composition:15 min to complete:
- Whole-body bed exercises + strength + functional retraining
- respiratory rehabilitation Frequency of sessions: 3×15 min/day
Other: Pulmonary and Motor Rehabilitation
Pulmonary and Motor Rehabilitation in ICU
Inclusion Criteria:
- Confirmed COVID-19 diagnosis, admitted to ICU with ARDS
Exclusion Criteria:
- Neuromuscular disease, severe heart failure (class IV), persistent severe hypotension
(systolic BP < 90mmHg), disorder of consciousness (DoC)
Teaching Hospital, University of Padova
Padova, Italy
Teaching Hospital, University of Verona
Verona, Italy
Alessandra Del Felice, MD, PhD
+39-0498212598
alessandra.delfelice@unipd.it
Alessandra Del Felice, MD, PhD, Principal Investigator
University of Padova